Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Caprelsa vandetanib regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Caprelsa vandetanib from AstraZeneca has "marginal" additional benefit

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE